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Original Research Article 
Seroprevalence of anti-mannose binding lectin autoantibodies in patients with 
rheumatoid arthritis in Sana'a city- Yemen 
Abstract 
Rheumatoid arthritis (RA) characterized by synovial inflammation and destruction of 
cartilage and bone. Until now there is no single test that diagnoses RA, however, several 
blood tests may suggest the presence of this disease. RA is associated with the presence 
of a number of autoantibodies as such as rheumatoid factor (RF), anti-cyclic citrullinated 
peptide (ACPA) and anti-mannose binding lectin (anti-MBL).  
This studyaimed firstly to investigate the presence of anti-MBL autoantibodies in the sera 
of RA patients and healthy controls and secondly to determine the diagnostic value of this 
marker in comparison with the classical RF, C- reactive protein (CRP) and ACPAamong 
RA cases. 
This case-control study was conducted at four health establishments; two public (Al-
Thawra Modern General Hospital and National Center of Central Public Health 
Laboratories) and two private (University of Science and Technology Hospital and Aulqi 
Specialized Medical Laboratories) in Sana'a city.  
Ninety-four individuals were enrolled in this study. Forty-seven persons were clinically 
diagnosed to have RA by a rheumatologist and 47 healthy subjects without RA were used 
as controls. Sera were separated and tested for presence of serum anti-MBL 
autoantibodies, ACPA, RF and CRP by a commercially available enzyme linked 
immunosorbent assay (ELISA) and latex agglutination technique.  
Study results showed that the meanSD for the levels of serum anti-MBL autoantibodies 
among RA cases were 394243 ng/ml which were significantly higher than that recorded 
among healthy controls (217173 ng/ml). The levels of serum anti-MBL autoantibodies 
were associated with positive RF and CRP tests (p=.02 & .007 respectively), but not with 
positive ACPA test (p=.42). 
The result of this study showed higher levels of serum anti-MBL autoantibodies among 
RA cases comparing with the healthy controlsand reveal an association with positive 
results for RF and CRP, but not with ACPA.Therefore, the anti-MBL antibody levels 
may associated with systemic autoimmune diseases and might not exclusive to RA. 
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Introduction 
Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects 0.5%–1% 
of the worldwide population. It is characterized by chronic and erosive polyarthritis 
which in the majority of patients leads to partial disability or to permanent handicap. The 
exact etiology of RA is unknownbut is believed to be influenced by genetic, 
environmental, hormonal, immunologic, and infectious factors
1,2
. 
The diagnosis of RA based onphysical exam, radiographic & laboratory tests. 
Unfortunately, there is no single test can confirm the diagnosis of RA. The blood tests, 
  
 
erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are only markers of 
inflammation. RA is characteristically associatedwith the presence of many different 
autoantibodies directed against multiple autoantigens. The first discovered autoantibody 
in RAwas rheumatoid factor (RF).It was found to react with theFc portion of IgG 
antibodies. Typically, RF is of IgM isotype, but IgG and IgA may also occur. RF is found 
in 60–80% of RA patients and thus is fairly sensitive in the RA diagnosis. However, the 
specificity of RF as a diagnostic marker for RA is low since it is frequently detected in 
many other conditions such as connective tissue diseases
3, 4
.Anti- citrullinated peptide 
antibody (ACPA) target peptides that are post-translationally modified by conversion of 
arginine to citrulline, occurs primarily in patients of RA and demonstrate a much higher 
specificity of 95.9% for RA.In addition, ACPA seem to be a better marker of poor 
prognostic features of progressive joint destruction
5, 6
.Mannose-binding lectin (MBL) is a 
liver-derived acute phase protein. This C type lectin has specific binding affinity to 
mannose and N-acetyl glucoseamine which structurally homologus to C1q, the 
component of classical complement pathway. When MBL binds to the specific 
carbohydrate, its associated serine proteases (MBL associated serine proteases "MSAPs") 
become activated, leading to activation of lectin pathwayof the complement system 
7-10
. 
MBL has an important role in provoking an inflammatory response and 
consequently has been well associated with the pathogenesis of different infectious and 
autoimmune diseases
11,13
. It has been shown that MBL binds both dimeric and polymeric 
IgA & activates complement
14
. Moreover, previous studies demonstrated that MBL can 
bind agalactosyl IgG& IgM including IgM RF complexes in RA patients, leading to 
generation of an inflammatory response
13, 15
.The presence of autoantibodies against MBL 
in serum as well as in synovial fluid from several RA patients has been reported by many 
studies
16- 19
, and they demonstrated that the anti-MBL decrease the functional activity of 
MBL in patients in SLE.This studyaimed firstly to investigate the presence of anti-MBL 
autoantibodies in the sera of patients with RA and healthy controls and secondly to 
determine the diagnostic value of this marker in comparison with the classical RF, CRP 
and ACPAamong RA cases. 
Subjects and Methods 
Subjects 
The type of study was a case-control study which was carried out during a period from 
May, 2015 to May, 2016at Al-thawra Modern General Hospital,University of Science 
and Technology Hospital, National Center of Central Public Health Laboratories, and 
Aulqi Specialized Medical Laboratories in Sana'a city.A total number of ninety-four 
Yemeni participants were investigated for the presence of anti-MBL autoantibodies in 
their sera. Forty-seven cases were clinically diagnosed with RA by a rheumatologist 
according to the ACR criteria 
20
.In addition, forty-seven healthy individuals without RA 
were enrolled as controls. A full history was taken from each personand recorded in a 
predesigned questionnaire.  
Five milliliter venous blood was collected from each participant into plain vacationer 
tubes. The sample was allowed to clot at room temperature and centrifuged at 3500 rpm 
for five minutes. Serum was then separated into eppendrof tubes and stored at -20 °C till 
tested. 
Autoantibody tests 
  
 
Presence of anti-MBL autoantibodies in the serum of each participant was tested using 
ELISA kit (Uscn, Life Science Inc, USA) and the presence of ACPA was also determined 
by ELISA (INOVA diagnostic kits, San Diego, CA-USA). RF and CRP were measured 
by latex tests (Vitro Scient Co, Egypt).Cutoff was calculated from the mean + 2SD of 
healthy controls which equals to 390 ng/ml 
Statistical analysis 
Statistical analysis was performed by using the Epi Info version 6 program (CDC, 
Atlanta, USA) for statistical significance. 
Results 
Out of the 47 cases with RA, females represented 81%, while males represented 19% 
with a mean age 43.3±14.8 years and 49% of ages were in group ≥50 years. In addition, 
out of the 47 healthy controls, females represented 83%, while males represented 17% 
with a mean age 43.2±14.9 years and 47% of ages were in group ≥50 years,(Table 1). 
The levels of serum anti-MBL autoantibodies were significantly increased among 
RA cases, in which the mean ± SD of anti-MBL levels among RA cases was 394± 243 
ng/ml higher than the mean ± SD of healthy controls which was 217± 173 ng/ml with a 
statistical significance (p=0.001), (Table 2). As regard the association of anti-MBL with 
other serological markers. The levels of serum anti-MBL autoantibodies were 
significantly higher among cases with RF and CRP positive than negative (418.4232, 
418.8229 ng/ml,respectively) and the other statistical variables as median, mode and 
ranges were also higher for cases than controls. On the other hand, the levels of anti-
MBL were higher among cases with ACPA negative 415.4208 ng/ml than positive 
376.8257 ng/ml (Table 3). 
Discussion 
At last years, a growing evidence showed the importance of innate immune system 
involving lectin pathway of complement activation, of which MBL play a crucial role 
21-
23
. The low level of MBL has been apparently associated with inflammatory autoimmune 
diseases such as RA, SLE and other related diseases, also the deficiency of MBL can 
enhance the risk of infection 
21, 24, 25
. The present study aimed firstly to investigate the 
presence of anti-MBL autoantibodies in the sera of patients with RA and secondly to 
determine the diagnostic value of this marker in comparing with the classical RF, CRP 
and ACPA. 
The results of this study showed an obvious measurableand a higher significant 
presence of anti-MBL autoantibodies in the sera of enrolled RA cases (meanSD= 394 ± 
243 ng/ml) as compared with healthy controls(meanSD= 217 ± 173 ng/ml)(p= 0.001). 
This result was similar to that reported by Gupta et al.
26
in India which showed a 
detectable significant presence of anti-MBL autoantibodies in the sera of RA patients as 
compared to the controls. This study demonstrated that the anti-MBL were more often in 
RA patient sera and suggested that it have a diagnostic value for RA.  
When considered the association of the levels of anti-MBL with the levels of RF 
and CRP in this patients,the anti-MBL autoantibody levels were significantlyassociated 
with the positive cases of these markers in which the meanSD of anti-MBL levels equal 
to 418.4232 &418.8229 ng/ml, respectively. Our results were in agreeingwith study by 
  
 
Di Muzio et al.
27
, and disagree with study by Gupta et al. which reported that the levels 
of anti-MBL antibodies were still positive and high in negative cases of RF & CRP
26
.  
As regard ACPA,there was no association between positive ACPA and the levels of 
anti-MBL autoantibodies, in which the meanSD of anti-MBL levels for ACPA positive 
cases was 376.8257 ng/ml, and for negative ACPA were 415.4208 ng/ml. To our 
knowledge, there is no previous study in the relation between anti-MBL levels and ACPA 
in RA patients that agreed or disagreed with our results.  
Several studies reported that the anti-MBL autoantibodies found in in different 
systemic autoimmune diseases as SLE and RA. These studies demonstrated that anti-
MBL autoantibodies play a pathogenic role in the development of autoimmunity 
16-19, 28, 
29
. Depend on the specificity of ACPA to RA
5, 6
and according to the association of anti-
MBL autoantibody levelswith positivity of RF and CRP but not with ACPA in our 
results, we can have concluded that the anti-MBL antibody levels may associated with 
systemic autoimmune diseases and might not exclusive to RA. 
Conclusion and recommendations 
In our study, the levels of serum anti-MBL autoantibody were significantly increased in 
RA cases when compared with the healthy controls and a significant association was 
found between the levels of serum anti-MBL autoantibody, RF and CRP positive results, 
but no association with ACPA positive results.Further studies should be applied to detect 
the diagnostic value of serum anti-MBL autoantibody levelsin RA as well as the 
molecular mechanism of its interaction inRA. 
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Table (1): The age and sex distribution of studied subjects for the levels of serum anti-
MBL autoantibodies 
Characteristics variable  
Cases n=47 Controls n=47 Total n=94 
No. % No. % No. % 
Sex  
female 38 81 39 83 77 81.9 
male 9 19 8 17 17 18.1 
Total 47 100 47 100 94 100 
Age groups/ Years  
<20 5 10.6 4 8.5 9 9.6 
20-29 7 14.9 10 21.3 17 18.1 
30-39 5 10.6 5 10.6 10 10.6 
40-49 7 14.9 6 13 13 13.8 
≥ 50 23 49 22 47 45 47.9 
Total 47 100 47 100 94 100 
Mean/Years ±SD 43.3 ± 14.8 43.2 ± 14.9 43.2 ± 14.8 
Min./Years 16  16  16  
Max./Years 66  66  66  
 
  
 
Table (2):Titer of anti-MBL autoantibodies in both RA patients and the controls 
Anti-MBL levels ng/ml Cases n=47 Controls n=47 p 
Mean± SD 394 ±243 217±173 <0.001 
Min. 15 14  
Max. 899.6 781  
 
Table (3):The association between geometric mean ± SD, median, mode and range for the 
levels of serum anti-MBL autoantibodies and positive and negative inflammatory markers 
among RA cases 
 
Inflammatory markers 
Anti-MBL autoantibodies levels ng/ml  
p Mean ±SD Median Mode Min.-Max. 
Anti-CCP 
Positive 376.8±257 318.5 597.5 15.2 – 894 
0.42 
 Negative 415.4±208 371 191 191-  781 
RF 
Positive 418.4±232 419 597.5 29.5 – 894 
0.02 
 Negative 300.7±265 232 15.2 15.2-781 
CRP 
Positive 418.8±229 419 597.5 29.4 – 894 
0.007 
Negative 277.8±273 191 15.2 15.2 – 781 
 
